Bibliographic information
GuidelineWHO guidelines on tuberculosis infection prevention and control: 2019 update
Year of Publication2019
Issuing InstitutionWHO
Recommendation
Maintained
Originally developed
In multidrug-resistant tuberculosis or rifampicin-resistant tuberculosis (MDR/RR-TB) patients on longer regimens that contain amikacin or streptomycin, an intensive phase of 6–7 months is suggested for most patients; the duration may be modified according to the patient’s response to therapy
Recommended in favor
Conditional
Certainty of evidence
Very low
Notes and Remarks
WHO standards for the adequate number and appropriate position of hand hygiene facilities should be implemented in all health care facilities.
Also Featured In
This recommendation also appears in the following guidelines:
Guideline
WHO consolidated guidelines on tuberculosis: module 1: prevention: infection prevention and control
Year2022
InstitutionWorld Health Organization